Bangkok, Thailand – 4 December 2024 – AstraZeneca Thailand, in collaboration with the Faculty of Medicine Siriraj Hospital, Mahidol University, has signed a Memorandum of Understanding (MoU) to jointly advance clinical research in Thailand through AstraZeneca’s innovative approaches. The initiative aims to enhance the capabilities of Thai researchers and broaden the scope of study for developing medicines and treatments within the country. By implementing
AstraZeneca’s clinical research model, the collaboration seeks to improve the efficiency of medical treatment research, aiming to elevate healthcare standards and enhance the quality of life for patients. The MoU signing ceremony was honored by Professor Apichat Asavamongkolkul, Dean of the Faculty of Medicine Siriraj Hospital, Mahidol University, and Mr. Roman Ramos, President of AstraZeneca Thailand.

Mr. Roman Ramos, President of AstraZeneca Thailand and Frontier Markets, stated, “At AstraZeneca, we prioritize clinical research to develop effective and safe medical treatments for patients. Our research currently spans a wide range of diseases, including oncology, cardiovascular, renal, and metabolic diseases, respiratory and immunology conditions, vaccine and immunotherapy development, as well as rare diseases. This MoU will enable AstraZeneca to bring our innovative resources, cutting-edge knowledge, and expertise in clinical research to Thai researchers. We aim to advance the development of medical treatments for severe diseases, significantly improving patients’ quality of life.”

Professor Apichat Asavamongkolkul, Dean of the Faculty of Medicine Siriraj Hospital, Mahidol University, shared, “The collaboration between the Faculty of Medicine Siriraj Hospital and AstraZeneca marks a significant milestone in our shared mission to advance medical research and innovation. By leveraging AstraZeneca’s cutting-edge expertise in medical development and Siriraj’s excellence in clinical research, we are dedicated to developing new treatments and ensuring early access to healthcare for patients. We believe this partnership will ultimately enhance better health standards in the future.” 

Associate Professor Winai Ratanasuwan, Director of Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj Hospital, Mahidol University, noted, “The key role of SICRES is to serve as a hub for conducting clinical research across various diseases, particularly those that pose significant challenges in Thailand and the region. This collaboration with AstraZeneca will further amplify the skills of clinical research personnel in Thailand through AstraZeneca’s global
knowledge network and innovations. Working collaboratively in centralised laboratories between Thai researchers and international partners will fully support the expansion of research, especially in developing new and effective medicines. This effort will provide more treatment options for patients in the future. Our close collaboration with AstraZeneca aims to provide opportunities for Thai people with access to new medicines and treatments, thereby increasing survival rates and
effectively reducing the severity of diseases.”

The signing ceremony also featured the academic seminar entitled, “Clinical Research: Bridging Innovation and Patient Care – The Path to Novel Treatments,” with an insights-sharing session from both AstraZeneca and researchers regarding the role of clinical research in driving therapeutic innovations and expanding patient access to effective treatments. The seminar concluded with a discussion on the benefits and challenges of enhancing treatment accessibility through clinical research. These valuable insights will serve as a foundation for future collaborative efforts between the two organizations.

About Siriraj Institute of Clinical Research (SICRES)
SICRES is an academic clinical research institute that operates under the Faculty of Medicine, Siriraj Hospital, Mahidol University. Our mission is to advance clinical research trials that transform patient care, improve human health, and enhance the community well-being. With a commitment to international standards, SICRES delivers cost-effective clinical research and offers comprehensive services for clinical trial design and management. Our vision is to become the most trusted academic clinical research organization in Southeast Asia. For more information, visit www.sicres.org/

About Faculty of Medicine Siriraj Hospital, Mahidol University
The Faculty of Medicine, Siriraj Hospital, established in 1888 by His Majesty King Chulalongkorn, is Thailand’s oldest medical institution. It is dedicated to produce high-caliber medical graduates conducting research, and providing medical services that meets the international standards. Siriraj Hospital is committed to improving health and quality of life for the people of Thailand and the global community. Learn more at www.2.si.mahidol.ac.th

About AstraZeneca
AstraZeneca (Securities abbreviation, AZN on LSE/STO/Nasdaq stock exchanges) is a leading global biopharmaceutical company focusing on discovering, developing, and distributing medicines for medicinal purposes, particularly the group of drugs among cancer, heart disease, kidney, metabolic system, and respiratory disease. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and has millions of patients worldwide benefiting from its innovative medicines. For more information, please visit astrazeneca.com and follow the company on facebook.com/AstraZeneca.TH